Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study

BACKGROUND: Polymyxin B is the first-line therapy for Carbapenem-resistant organism (CRO) nosocomial pneumonia. However, clinical data for its pharmacokinetic/pharmacodynamic (PK/PD) relationship are limited. This study aimed to investigate the relationship between polymyxin B exposure and efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Tiantian, Li, Ying, Xu, Ping, Zhong, Yanjun, Yang, Min, Ma, Wanjun, Xiang, Daxiong, Zhang, Bikui, Zhou, Yangang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142183/
https://www.ncbi.nlm.nih.gov/pubmed/37106370
http://dx.doi.org/10.1186/s13054-023-04448-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142183/
https://www.ncbi.nlm.nih.gov/pubmed/37106370
http://dx.doi.org/10.1186/s13054-023-04448-z

Ejemplares similares